AstraZeneca, which has pledged it won't make a profit on the vaccine during the pandemic, has reached agreements with governments and worldwide health organizations that put its cost at about $2.50 per dose.
The European Union struck a deal on Tuesday for up to 160 million doses of Moderna's vaccine candidate, taking the bloc's potential stock of COVID-19 shots to almost 2 billion.
The Oxford vaccine is also easy to store and transport, requiring refrigeration at between 2 and 8 C, whereas the treatments from Pfizer and Moderna must be kept at much colder temperatures for long-term storage. The committee will review an application for an emergency use authorization of the vaccine.
Pfizer Inc with partner BioNTech SE and Moderna Inc have released trial data showing their COVID-19 vaccines to be about 95% effective at preventing the illness, while AstraZeneca Plc this week said its vaccine could be up to 90% effective.
Snapchat takes on TikTok with new Spotlight feature
Snapchat has said that it will split $ 1 million between the most popular creators on the Snapchat platform every day. Spotlight is being described as Snapchat's answer to TikTok as it allows users to create similar types of content.
The company had said that 131 people contracted the virus but failed to explain how many of them were given the vaccine and how many of them did not. Drug firm Moderna said it will apply soon for its vaccine. "That's enough to vaccinate 20 million people", he said.
Vaccine makers and governments have negotiated varying prices, not all of which are public.
In addition, he said that now no Australians were on ventilators in hospital due to COVID-19, adding, "It says that Australians are winning". Governments have paid from a few dollars per AstraZeneca shot to up to $50 for the two-dose Pfizer regimen.
New Delhi, Nov 25 (IANS) At a time the world is racing against time to find a safe and effective vaccine against Covid-19, Union Health Minister Harsh Vardhan on Wednesday said that India has initiated looking at robust vaccine manufacturing and delivering ecosystem to meet demand in the coming days.
Further late-stage trial results for the Oxford vaccine are forthcoming, with data from 60,000 participants in the US, Kenya, Japan and India expected later this year.